Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company ...

Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.

CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

Recent: Bitcoin may reach $150K or $400K in 2025, based on SBR and Fed rates Layer-1 (L1s) blockchain protocols are the closest to network states. Yet there is little noise around L1s adopting ...

The Alfredson protocol is a treatment for Achilles tendonitis that involves repeated eccentric heel drop exercises. In this exercise, the heel is slowly lowered off a step while the toes stay on the ...